LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Former Distributor Wins “Breach of Contract” Suit Against NuVasive
Legal & Regulatory and Reimbursement

Former Distributor Wins “Breach of Contract” Suit Against NuVasive

March 3, 2016 2 min read Premium comments

Advertisement

Former Distributor Wins “Breach of Contract” Suit Against NuVasive
Source: Wikimedia Commons and StockMonkeys.com
Secondary

After a 13-day trial and 5 hours of deliberation, a federal jury in California found that NuVasive, Inc. breached its contract with a Nevada-based distributor named Madsen Medical.

The finding on February 19, 2016 was followed four days later by the jury awarding $41.8 million to Madsen Medical and its owner Kris Madsen.

According to court documents, Madsen alleged that NuVasive fired her distributorship in 2012 and then “lured” six of her reps to sell directly for their former Madsen clients in Las Vegas and Reno, Nevada.

The jury added punitive damages of $20 million to compensatory damages of $7.5 million, plus $14 million for unjust enrichment and $300, 000 in back commissions, according to plaintiff’s attorneys Huang, Ybarra, Singer & May.

Madsen’s attorney told jurors NuVasive had not only broken its contract but acted with “malice, fraud or oppression” and the knowledge that what it was doing was wrong. He asked the jury to award Madsen an additional $15 million in damages, for that allegedly malicious behavior.

NuVasive’s attorney told jurors that NuVasive’s behavior did not rise to the level required for punitive damages of any amount.

According to San Diego’s NBC 7, NuVasive will not have to pay both the $7.5 compensatory damages and the $14 million unjust enrichment award. Instead, Judge Barry Ted Moskowitz will review the evidence and verdict and consider post-trial written arguments from both sides before deciding which of the two damage amounts—either $7.5 million or $14 million—NuVasive will have to pay Madsen, if affirmed.

“We are aware that the court in the Madsen case reached a verdict unfavorable to NuVasive, and we are in the process of filing post-trial motions to overturn the verdict and/or seek a new trial, ” the company said in a statement to NBC 7. “We believe that neither the law nor the facts support the verdict in this matter, and we intend to appeal in the event our post-trial motions are unsuccessful and a judgment is entered by the Court. As this is an ongoing litigation matter, our policy is not to comment further.”

Advertisement

NuVasive Suit Previously Dismissed

In August 2015, according to Madsen’s attorneys, the federal court dismissed a lawsuit filed by NuVasive against Madsen for breach of contract, unfair competition, and intentional interference with contractual relations based on Madsen’s having allegedly made threats and disparaging statements about NuVasive. NuVasive also sued Madsen Medical for failure to return medical equipment after the manufacturer-distributor relationship between NuVasive and Madsen Medical terminated.

Her attorneys said the federal judge granted the dismissal because NuVasive did not have sufficient evidence to proceed to trial on its claims, particularly in light of deposition testimony and documentary evidence that “flatly contradicted” NuVasive’s allegations.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy